An 18-year follow-up after the first successful heart-lung transplant in Poland. Authors’ tribute to the pioneers of heart and lung transplantation by Zembala, Marian et al.
S H O R T  C O M M U N I C A T I O N   The first successful heart ‑lung transplant in Poland 773
hypertension. The patient has survived over 18 
years in good general condition.
Methods The analyzed medical records in‑
cluded findings obtained during the 18‑year 
follow‑up of this patient. Detailed data on 
the medical test results of the study patient are 
presented in the Supplementary material and 
include spirometry (Figures S1 and S2), echo‑
cardiography (Table S1), laboratory test (Table 
S2), and magnetic resonance imaging (Table S3). 
The patient’s written consent was required for 
participation in the study. The study obtained 
the ethics committee approval. No statistical 
analysis was performed.
Results and discussion A 37‑year ‑old man un‑
derwent HLTx due to end ‑stage dilated cardio‑
myopathy complicated with severe pulmonary 
embolism and pulmonary hypertension. The dis‑
ease onset was difficult to determine because of 
lack of medical records and incomplete patient’s 
history. To our best knowledge, the patient had 
a 16‑year history of cigarette smoking and no 
family history of cardiac or pulmonary disease. 
He worked as a metal press operator. At the age of 
35 years, the patient started complaining of chest 
pain, dyspnea, and poor exercise capacity. Symp‑
toms occurred after severe bacterial pneumonia 
and myocarditis was suspected. Due to progres‑
sive heart failure, the patient was admitted to 
Introduction Heart ‑lung transplant (HLTx) 
is the procedure of choice in patients with 
concomitant advanced cardiopulmonary fail‑
ure. For the first time, it was successfully car‑
ried out by Bruce A. Reitz in 1982 in patients 
with pulmonary vascular diseases.1 Accord‑
ing to the registry of the International Soci‑
ety of Heart and Lung Transplantation (ISHLT), 
more than 4000 patients have underwent HLTx 
from that time.2 Thoracic organ transplant pro‑
grams could be initiated thanks to James Hardy 
who performed the first single lung transplant, 
Christiaan Barnard who conducted the first 
heart transplant, and Joel D. Cooper—the fa‑
ther of the first successful single and double 
lung transplants.3
In Poland, the first attempts to conduct HLTx 
to save patients with cardiopulmonary failure 
were started in 1986, but turned out to be inef‑
fective. The first successful combined heart ‑lung 
transplant in Poland was performed in 2001. So 
far, it has been the only successful HLTx carried 
out there. According to the archives of the Sile‑
sian Center for Heart Diseases (SCHD), more 
than 200 lung and 1200 heart transplants have 
been performed in our center so far.
In this short communication, we describe 
the case of the first patient in Poland who un‑
derwent combined heart ‑lung transplant due 
to dilated cardiomyopathy complicated with 
severe pulmonary embolism and pulmonary 
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desaturation) in a 6‑minute walk test. At pres‑
ent, the patient’s condition is stable.
According to the ISHLT registry, 4054 heart‑
‑lung transplants were performed in adults in 
June 2017. The registry also included 1‑ and 
5‑year occurrence rates of comorbidities: dia‑
betes, 17.1% and 26.5%; arterial hypertension, 
59.1% and 87.2%; and hyperlipidemia, 28% and 
70.4%, respectively. The cumulative incidence of 
severe renal dysfunction in 5‑year survivors was 
13.7%.2 Our patient developed diabetes, arterial 
hypertension, and hyperlipidemia 2 years after 
HLTx, but kidney function was stable after al‑
most 2 decades after surgery. These comorbidi‑
ties could be related to post ‑transplant immu‑
nosuppressive therapy.4
Harringer et al5 and Moffatt ‑Bruce at al6 as‑
sessed 1‑ and 5‑year survival rates after HLTx 
and showed 77% versus 87% and 64% versus 
63%, respectively. According to a literature re‑
view, the survival rate after HLTx compared with 
single or double lung transplant is comparable, 
similar to the values cited above.7‑10 The authors 
of the 2018 ISHLT registry investigated the sur‑
vival rate of all HLTx recipients from 1982 to 
June 2016. One ‑year survival was reached by 
63% of the patients, 5‑year survival by 45%, and 
10‑year survival by 32%.11
Postoperative management after HLTx is 
similar to that after lung transplant.9,10 Ear‑
ly complications occurring after surgery are 
much more common to lung graft than the car‑
diac one. Yusen et al11 showed that obliterative 
bronchiolitis occurs more frequently than cor‑
onary vasculopathy (28.7% vs 8.2%). Obliter‑
ative bronchiolitis and chronic lung allograft 
dysfunction are also the major causes of mor‑
tality at 1‑year follow ‑up.11 Maintenance immu‑
nosuppression and blood concentrations of im‑
munosuppressive medications, which should be 
reached, are comparable to those used after lung 
transplant, being greater than after orthotop‑
ic heart transplant alone. Immunosuppression 
can be decreased 1 year after transplant, depend‑
ing on the patient’s history of rejection episodes 
and adverse effects from the medications. In re‑
cipients who remain stable, doses of calcineurin 
inhibitors and corticosteroids may be reduced.12 
Additionally, persistent or virulent infections 
require reduction of immunosuppression more 
quickly. The man described in this short com‑
munication received cyclosporine, prednisolone, 
and sirolimus during the first year after trans‑
plant. Then, corticosteroids were discontinued 
and blood concentrations of cyclosporine were 
reduced. Severe infection, which occurred after 
the first decade after HLTx, forced a modifica‑
tion in drug therapy. Currently, the patient re‑
ceives only sirolimus and no signs of graft rejec‑
tion are observed.
In summary, HLTx is an effective therapeutic 
option for patients with end ‑stage cardiac and 
the SCHD for diagnostic workup. Coronary cath‑
eterization showed no abnormalities in the cor‑
onary arteries, and myocardial biopsy revealed 
dilated cardiomyopathy. Based on clinical status, 
the patient was considered as a potential heart 
transplant recipient. Since August 2001, the pa‑
tient presented heart failure exacerbation due 
to pulmonary embolism complicated with pul‑
monary hypertension. For this reason, he was 
deemed eligible for heart ‑lung transplant. Twen‑
ty days thereafter, uncomplicated, orthotopic 
HLTx was performed. The procedure was con‑
ducted with sternotomy access. Both the heart 
and the lungs were very carefully dissected and 
excised. Then, the donor’s heart was implanted 
with the Reitz technique. The trachea, the aor‑
ta, and the right atrium were fused. The proce‑
dure lasted 9 hours 20 minutes, the cardiopul‑
monary bypass time was 4 hours 38 minutes, 
and the organ ischemic time was 3 hours 57 min‑
utes. In the postoperative course, acute rejection 
of transplanted organs occurred twice. The pa‑
tient received the following immunosuppres‑
sion therapy: cyclosporine (400 mg/d reaching 
371.5 ng/ml of blood concentration), sirolimus 
(4.5 mg/d), and prednisolone (4 mg/d). The man 
was discharged from the hospital on postopera‑
tive day 86. A year after HLTx, during a follow‑
‑up visit in the SCHD, the patient’s clinical sta‑
tus was improving. Immunosuppression thera‑
py was modified—prednisolone was discontin‑
ued. During the first decade after transplant, 
the patient was hospitalized a few times due to 
bronchiolitis; however, he remained in a good 
general condition. Unfortunately, 10 years af‑
ter HLTx, the patient had a single serious, life‑
‑threatening infection. He was urgently admit‑
ted to the SCHD because of symptoms of se‑
vere pneumonia. The dominant manifestations 
were high fever, cough with expectoration, and 
sore throat. High ‑resolution computed tomog‑
raphy showed consolidations in segment 6 of 
the right lung and less severe consolidations in 
the left lung. Ground glass opacities were pres‑
ent at the bases of both lungs. Bronchoalveolar 
lavage  was performed and Aspergillus species 
and carbapenem ‑resistant Pseudomonas aerugino-
sa were detected. Infection was treated based on 
the microbiological test results, with amphoter‑
icin and caspofungin, which were continued for 
a month and a half. Immunosuppressive therapy 
was further modified: cyclosporine was discon‑
tinued, and sirolimus was maintained (1 mg ev‑
ery 4 days). After 2 months of treatment, the pa‑
tient was discharged in a good general condition.
Currently, the  patient is 18 years after 
the HLTx procedure. The post‑transplant time 
has been complicated by type 2 diabetes, dys‑
lipidemia, and arterial hypertension. During 
the last follow ‑up hospitalization in the SCHD, 
the patient achieved the distance of 535.4 m 
(3 points according to the Borg scale, without 
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pulmonary disease. Although it is a risky pro‑
cedure, burdened with high mortality and a low 
survival rate, it sometimes may be the only life‑
‑saving method. Proper patient care both be‑
fore and after the surgery can significantly ex‑
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